InnoCan Pharma Corporation (CSE:INNO)

Canada flag Canada · Delayed Price · Currency is CAD
6.65
-0.15 (-2.21%)
At close: Mar 20, 2026
Market Cap29.92M -37.5%
Revenue (ttm)37.64M -6.6%
Net Income-4.50M
EPS-1.01
Shares Out4.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume300
Average Volume1,932
Open6.81
Previous Close6.80
Day's Range6.65 - 6.81
52-Week Range5.76 - 21.00
Beta-0.18
RSI45.28
Earnings DateMar 31, 2026

About InnoCan Pharma

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments: Pharmaceuticals and Consumer Wellness. The company's Pharmaceutical segment engages in the development of drug delivery technologies for both human and animal health applications, based on advanced cannabinoids science. It offers a Cannabidiol-loaded Liposome injection Platform (LPT-CBD) that facilitates dosing and release of synthetic cannabidiol into the blood stream for t... [Read more]

Founded 2017
Employees 5
Stock Exchange Canadian Securities Exchange
Ticker Symbol INNO
Full Company Profile

Financial Performance

In 2024, InnoCan Pharma's revenue was $29.44 million, an increase of 115.55% compared to the previous year's $13.66 million. Losses were -$1.83 million, -60.98% less than in 2023.

Financial numbers in USD Financial Statements